Antipsychotic medication, functional outcome and quality of life in schizophrenia: focus on amisulpride

References

• Awad AG, Hogan TP, Voruganti LN, et al. Patients’ subjective experiences on antipsychotic medications: implications for outcome and quality of life. Int Clin Psychopharmacol 1995;10(Suppl. 3):123-32
   PubMed Web of Science ®Google Scholar
• Awad AG, Lapierre YD, Angus C, et al. Quality of life and response of negative symptoms in schizophrenia to haloperidol and the atypical antipsychotic remoxipride. The Canadian Remoxipride Group. J Psychiatry Neurosci 1997;22:244-8
   PubMed Web of Science ®Google Scholar
• Voruganti L, Heslegrave R, Awad AG, et al. Quality of life measurement in schizophrenia: reconciling the quest for subjectivity with the question of reliability. Psychol Med 1998;28:165-72
   PubMed Web of Science ®Google Scholar
• Marwaha S, Johnson S, Bebbington P, et al. Correlates of subjective quality of life in people with schizophrenia: findings from the EuroSC study. J Nerv Ment Dis 2008;196:87-94
   PubMed Web of Science ®Google Scholar
• Heider D, Angermeyer MC, Winkler I, et al. A prospective study of quality of life in schizophrenia in three European countries. Schizophr Res 2007;93:194-202
   PubMed Web of Science ®Google Scholar
• Meijer CJ, Koeter MW, Sprangers MA, et al. Predictors of general quality of life and the mediating role of health related quality of life in patients with schizophrenia. Soc Psychiatry Psychiatr Epidemiol 2009;44:361-8
   PubMed Web of Science ®Google Scholar
• Hofer A, Kemmler G, Eder U, et al. Quality of life in schizophrenia: the impact of psychopathology, attitude toward medication, and side effects. J Clin Psychiatry 2004;65:932-9
   PubMed Web of Science ®Google Scholar
• Salome F, Petitjean F, Germain C, et al. [The subjective quality of life of patients with schizophrenia: influence of psychopathology and patients’ expectations. A comparative study]. Encephale 2004;30:60-8
   PubMed Web of Science ®Google Scholar
• Meltzer HY, Burnett S, Bastani B, et al. Effects of six months of clozapine treatment on the quality of life of chronic schizophrenic patients. Hosp Community Psychiatry 1990;41:892-7
   PubMedGoogle Scholar
• Tek C, Kirkpatrick B, Buchanan RW. A five-year followup study of deficit and nondeficit schizophrenia. Schizophr Res 2001;49:253-60
   PubMed Web of Science ®Google Scholar
• Yamauchi K, Aki H, Tomotake M, et al. Predictors of subjective and objective quality of life in outpatients with schizophrenia. Psychiatry Clin Neurosci 2008;62:404-11
   PubMed Web of Science ®Google Scholar
• Delamillieure P, Ochoa-Torres D, Vasse T, et al. The subjective quality of life in deficit and nondeficit schizophrenic patients. Eur Psychiatry 2005;20:346-8
   PubMed Web of Science ®Google Scholar
• Norman RM, Malla AK, Cortese L, et al. Symptoms and cognition as predictors of community functioning: a prospective analysis. Am J Psychiatry 1999;156:400-5
   PubMed Web of Science ®Google Scholar
• Awad AG, Voruganti LN, Heslegrave RJ. A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation. Qual Life Res 1997;6:21-6
   PubMed Web of Science ®Google Scholar
• Lindstrom E, Bingefors K. Patient compliance with drug therapy in schizophrenia. Economic and clinical issues. Pharmacoeconomics 2000;18:106-24
   PubMed Web of Science ®Google Scholar
• Hellewell JS. Patients’ subjective experiences of antipsychotics: clinical relevance. CNS Drugs 2002;16:457-71
   PubMed Web of Science ®Google Scholar
• Voruganti L, Cortese L, Oyewumi L, et al. Comparative evaluation of conventional and novel antipsychotic drugs with reference to their subjective tolerability, side-effect profile and impact on quality of life. Schizophr Res 2000;43:135-45
   PubMed Web of Science ®Google Scholar
• Mortimer AM, Al-Agib AO. Quality of life in schizophrenia on conventional versus atypical antipsychotic medication: a comparative cross-sectional study. Int J Soc Psychiatry 2007;53:99-107
   PubMed Web of Science ®Google Scholar
• Ritsner M, Gibel A, Perelroyzen G, et al. Quality of life outcomes of risperidone, olanzapine, and typical antipsychotics among schizophrenia patients treated in routine clinical practice: a naturalistic comparative study. J Clin Psychopharmacol 2004;24:582-91
   PubMed Web of Science ®Google Scholar
• Divanon F, Delamillieure P, Lehaguez A, et al. [Comparative evaluation of quality of life in patients with schizophrenia treated with conventional versus atypical neuroleptics: results of a transversal study]. Encephale 2006;32(4 Pt 1):459-65
   Web of Science ®Google Scholar
• Swartz MS, Perkins DO, Stroup TS, et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry 2007;164:428-36
   PubMed Web of Science ®Google Scholar
• Haro JM, Novick D, Suarez D, et al. Remission and relapse in the outpatient care of schizophrenia: three-year results from the Schizophrenia Outpatient Health Outcomes study. J Clin Psychopharmacol 2006;26:571-8
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Keet IP, Kahn RS. The European First Episode Schizophrenia Trial (EUFEST): rationale and design of the trial. Schizophr Res 2005;78:147-56
   PubMed Web of Science ®Google Scholar
• Awad AG, Voruganti LN. New antipsychotics, compliance, quality of life, and subjective tolerability – are patients better off?. Can J Psychiatry 2004;49:297-302
   PubMed Web of Science ®Google Scholar
• McKeage K, Plosker GL. Amisulpride: a review of its use in the management of schizophrenia. CNS Drugs 2004;18:933-56
   PubMed Web of Science ®Google Scholar
• Peuskens J, Moller HJ, Puech A. Amisulpride improves depressive symptoms in acute exacerbations of schizophrenia: comparison with haloperidol and risperidone. Eur Neuropsychopharmacol 2002;12:305-10
   PubMed Web of Science ®Google Scholar
• Vanelle JM, Douki S. A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression. Eur Psychiatry 2006;21:523-30
   PubMed Web of Science ®Google Scholar
• Thomas P, Alptekin K, Gheorghe M, et al. Management of patients presenting with acute psychotic episodes of schizophrenia. CNS Drugs 2009;23:193-212
   PubMed Web of Science ®Google Scholar
• Storosum JG, Elferink AJ, van Zwieten BJ, et al. Amisulpride: is there a treatment for negative symptoms in schizophrenia patients?. Schizophr Bull 2002;28:193-201
   PubMed Web of Science ®Google Scholar
• Leucht S, Pitschel-Walz G, Engel RR, et al. Amisulpride, an unusual ‘atypical’ antipsychotic: a meta-analysis of randomized controlled trials. Am J Psychiatry 2002;159:180-90
   PubMed Web of Science ®Google Scholar
• Leucht S, Corves C, Arbter D, et al. Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009;373:31-41
   PubMed Web of Science ®Google Scholar
• Saleem P, Olie JP, Loo H. Social functioning and quality of life in the schizophrenic patient: advantages of amisulpride. Int Clin Psychopharmacol 2002;17:1-8
   PubMed Web of Science ®Google Scholar
• Bobes J, Garcia-Portilla P, Saiz PA, et al. Quality of life measures in schizophrenia. Eur Psychiatry 2005;20(Suppl. 3):S313-7
   PubMed Web of Science ®Google Scholar
• Alonso J, Croudace T, Brown J, et al. Health-related quality of life (HRQL) and continuous antipsychotic treatment: 3-year results from the Schizophrenia Health Outcomes (SOHO) study. Value Health 2009;12:536-43
   PubMed Web of Science ®Google Scholar
• Heinrichs RW. Verbal responses to human figure paintings: a test of the uncertainty hypothesis. Can J Psychol 1984;38:512-18
   PubMed Web of Science ®Google Scholar
• Naber D. A self-rating to measure subjective effects of neuroleptic drugs, relationships to objective psychopathology, quality of life, compliance and other clinical variables. Int Clin Psychopharmacol 1995;10(Suppl. 3):133-8
   PubMed Web of Science ®Google Scholar
• Heinrichs DW, Hanlon TE, Carpenter WT Jr. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984;10:388-98
   PubMed Web of Science ®Google Scholar
• Cramer JA, Rosenheck R, Xu W, et al. Quality of life in schizophrenia: a comparison of instruments. Department of Veterans Affairs Cooperative Study Group on Clozapine in Refractory Schizophrenia. Schizophr Bull 2000;26:659-66
   PubMed Web of Science ®Google Scholar
• Rabin R, de Charro F. EQ-5D: a measure of health status from the EuroQol Group. Ann Med 2001;33:337-43
   PubMed Web of Science ®Google Scholar
• Priebe S, Huxley P, Knight S, et al. Application and results of the Manchester Short Assessment of Quality of Life (MANSA). Int J Soc Psychiatry 1999;45:7-12
   PubMed Web of Science ®Google Scholar
• Gilchrist A, Taylor M, Wright M, et al. Is olanzapine clinically effective? A naturalistic outcome survey in two hospital settings. Pharmaceut J 2002;269:222-5
   Google Scholar
• Jones SH, Thornicroft G, Coffey M, et al. A brief mental health outcome scale – reliability and validity of the Global Assessment of Functioning (GAF). Br J Psychiatry 1995;166:654-9
   PubMed Web of Science ®Google Scholar
• Goldman HH, Skodol AE, Lave TR. Revising axis V for DSM-IV: a review of measures of social functioning. Am J Psychiatry 1992;149:1148-56
   PubMed Web of Science ®Google Scholar
• Jette AM. The Functional Status Index: reliability and validity of a self-report functional disability measure. J Rheumatol Suppl 1987;14(Suppl. 15):15-21
   PubMedGoogle Scholar
• American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th edition (DSM-IV). Washington DC: American Psychiatric Association, 1994
   Google Scholar
• Lôo H, Poirier-Littre MF, Theron M, et al. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia. Br J Psychiatry 1997;170:18-22
   PubMed Web of Science ®Google Scholar
• Carrière P, Bonhomme D, Lemperiere T. Amisulpride has a superior benefit/risk profile to haloperidol in schizophrenia: results of a multicentre, double-blind study (the Amisulpride Study Group). Eur Psychiatry 2000;15:321-9
   PubMed Web of Science ®Google Scholar
• Colonna L, Saleem P, Dondey-Nouvel L, et al. Long-term safety and efficacy of amisulpride in subchronic or chronic schizophrenia. Amisulpride Study Group. Int Clin Psychopharmacol 2000;15:13-22
   PubMed Web of Science ®Google Scholar
• Sechter D, Peuskens J, Fleurot O, et al. Amisulpride vs. risperidone in chronic schizophrenia: results of a 6-month double-blind study. Neuropsychopharmacology 2002;27:1071-81
   PubMed Web of Science ®Google Scholar
• Hwang TJ, Lee SM, Sun HJ, et al. Amisulpride versus risperidone in the treatment of schizophrenic patients: a double-blind pilot study in Taiwan. J Formos Med Assoc 2003;102:30-6
   PubMed Web of Science ®Google Scholar
• Mortimer A, Martin S, Loo H, et al. A double-blind, randomized comparative trial of amisulpride versus olanzapine for 6 months in the treatment of schizophrenia. Int Clin Psychopharmacol 2004;19:63-9
   PubMed Web of Science ®Google Scholar
• Lecrubier Y, Quintin P, Bouhassira M, et al. The treatment of negative symptoms and deficit states of chronic schizophrenia: olanzapine compared to amisulpride and placebo in a 6-month double-blind controlled clinical trial. Acta Psychiatr Scand 2006;114:319-27
   PubMed Web of Science ®Google Scholar
• Olié JP, Spina E, Murray S, et al. Ziprasidone and amisulpride effectively treat negative symptoms of schizophrenia: results of a 12-week, double-blind study. Int Clin Psychopharmacol 2006;21:143-51
   PubMed Web of Science ®Google Scholar
• Surguladze S, Patel A, Kerwin RW, et al. Cost analysis of treating schizophrenia with amisulpride: naturalistic mirror image study. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:517-22
   PubMed Web of Science ®Google Scholar
• Taylor M, Turner M, Watt L, et al. Atypical anti-psychotics in the real world – a naturalistic comparative outcome study. Scott Med J 2005;50:102-6
   PubMed Web of Science ®Google Scholar
• Lambert M, Naber D, Eich FX, et al. Remission of severely impaired subjective wellbeing in 727 patients with schizophrenia treated with amisulpride. Acta Psychiatr Scand 2007;115:106-13
   PubMed Web of Science ®Google Scholar
• Novick D, Haro JM, Suarez D, et al. Recovery in the outpatient setting: 36-month results from the Schizophrenia Outpatients Health Outcomes (SOHO) study. Schizophr Res 2009;108:223-30
   PubMed Web of Science ®Google Scholar
• Novick D, Haro JM, Perrin E, et al. Tolerability of outpatient antipsychotic treatment: 36-month results from the European Schizophrenia Outpatient Health Outcomes (SOHO) study. Eur Neuropsychopharmacol 2009;19:542-50
   PubMed Web of Science ®Google Scholar
• Kahn RS, Fleischhacker WW, Boter H, et al. Effectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trial. Lancet 2008;371:1085-97
   PubMed Web of Science ®Google Scholar
• Kusel Y, Laugharne R, Perrington S, et al. Measurement of quality of life in schizophrenia: a comparison of two scales. Soc Psychiatry Psychiatr Epidemiol 2007;42:819-23
   PubMed Web of Science ®Google Scholar
• Bengtsson-Tops A, Hansson L, Sandlund M, et al. Subjective versus interviewer assessment of global quality of life among persons with schizophrenia living in the community: a Nordic multicentre study. Qual Life Res 2005;14:221-9
   PubMed Web of Science ®Google Scholar